

Contents

Preface XIII

List of Contributors XV

1 Development of Sustainable Biocatalytic Reduction Processes for Organic Chemists 1

Roland Wohlgemuth

- 1.1 Introduction 1
 - 1.2 Biocatalytic Reductions of C=O Double Bonds 3
 - 1.2.1 Biocatalytic Reductions of Ketones to Alcohols 3
 - 1.2.2 Biocatalytic Reductions of Aldehydes to Alcohols 6
 - 1.2.3 Biocatalytic Reductions of Carboxylic Acids to Aldehydes 8
 - 1.2.4 Biocatalytic Reductions of Carboxylic Acids to Alcohols 8
 - 1.3 Biocatalytic Reductions of C=C Double Bonds 8
 - 1.4 Biocatalytic Reductions of Imines to Amines 10
 - 1.5 Biocatalytic Reductions of Nitriles to Amines 12
 - 1.6 Biocatalytic Deoxygenation Reactions 12
 - 1.7 Emerging Reductive Biocatalytic Reactions 14
 - 1.8 Reaction Engineering for Biocatalytic Reduction Processes 16
 - 1.9 Summary and Outlook 17
- References 18

2 Reductases: From Natural Diversity to Established Biocatalysis and to Emerging Enzymatic Activities 27

Elena Fernández-Álvaro and Pablo Domínguez de María

- 2.1 Reductases: Natural Occurrence and Context for Biocatalysis 27
- 2.2 Emerging Cases of Reductases in Biocatalysis 36
 - 2.2.1 Motivation: The Quest for Novel Enzymes and Reactivities 36
 - 2.2.2 Imine Reductases 36
 - 2.2.3 Nitrile Reductases: The Next Member in the Portfolio of Reductases? 38
 - 2.2.4 Other Emerging N-Based Enzymatic Reductions: Nitroalkenes and Oximes 41
 - 2.2.5 From Carboxylic Acids to Alcohols: Biocatalysis 42

2.3	Concluding Remarks	44
	References	44
3	Synthetic Strategies Based on C=C Bioreductions for the Preparation of Biologically Active Molecules	49
	<i>Francesco G. Gatti, Fabio Parmeggiani, and Alessandro Sacchetti</i>	
3.1	Introduction	49
3.2	Bioreduction of α,β -Unsaturated Carbonyl Compounds	53
3.2.1	Aldehydes	54
3.2.2	Ketones	61
3.3	Bioreduction of Nitroolefins	65
3.4	Bioreduction of α,β -Unsaturated Carboxylic Acids and Derivatives	68
3.4.1	Monoesters and Lactones	68
3.4.2	Diesters	71
3.4.3	Carboxylic Acids	73
3.4.4	Anhydrides and Imides	73
3.5	Bioreduction of α,β -Unsaturated Nitriles	74
3.6	Concluding Remarks	76
	References	77
4	Synthetic Strategies Based on C=O Bioreductions for the Preparation of Biologically Active Molecules	85
	<i>Antbal Cuetos, Alba Díaz-Rodríguez, and Iván Lavandera</i>	
4.1	Introduction	85
4.2	Synthesis of Biologically Active Compounds through C=O Bioreduction	87
4.2.1	Keto Esters	87
4.2.1.1	α -Keto Esters	87
4.2.1.2	β -Keto Esters	89
4.2.1.3	Other Keto Esters	89
4.2.2	Diketones	90
4.2.3	α -Halo Ketones	91
4.2.4	(Hetero)Cyclic Ketones	94
4.2.5	“Bulky–Bulky” Ketones	96
4.2.6	Miscellaneous	98
4.3	Other Strategies to Construct Biologically Active Compounds	99
4.4	Summary and Outlook	106
	References	107
5	Protein Engineering: Development of Novel Enzymes for the Improved Reduction of C=C Double Bonds	113
	<i>Sabrina Kille and Manfred T. Reetz</i>	
5.1	Introduction	113
5.2	The Protein Engineering Process and Employed Mutagenesis Methods	114

- 5.3 Examples of Rational Design of Old Yellow Enzymes 117
- 5.4 Evolving Old Yellow Enzymes (OYEs) 117
- 5.4.1 Evolving OYE1 as a Catalyst in the Stereoselective Reduction of 3-Alkyl-2-cyclohexenone Derivatives and Baylis–Hillman Adducts 119
- 5.4.2 Evolving the Pentaerythritol Tetranitrate (PETN) Reductase as a Catalyst in the Reduction of α,β -Unsaturated Carbonyl Compounds and E-Nitroolefins 123
- 5.4.3 Evolving Nicotinamide-Dependent 2-Cyclohexenone Reductase (NCR) from *Zymomonas mobilis* for the Reduction of α,β -Unsaturated Ketones 129
- 5.4.4 Evolving the YqjM from *Bacillus subtilis* for Enhanced Activity, Substrate Scope, and Stereoselectivity in the Reduction of α,β -Unsaturated Ketones 129
- 5.5 Conclusions and Perspectives 134
- References 134

- 6 Protein Engineering: Development of Novel Enzymes for the Improved Reduction of C=O Double Bonds 139**
Nobuya Itoh and Yoshihide Makino
- 6.1 Introduction 139
- 6.2 Detailed Characterization of PAR 140
- 6.2.1 Location of PAR in Styrene Metabolic Pathway 140
- 6.2.2 Physicochemical Properties of PAR 142
- 6.2.3 Enzymatic Properties of PAR 147
- 6.2.4 Docking Model Construction of PAR 151
- 6.3 Detailed Characterization of LSADH 151
- 6.3.1 Screening of LSADH from Styrene-Assimilating Soil Microorganisms 151
- 6.3.2 Physicochemical Properties of LSADH 153
- 6.3.3 Enzymatic Properties of LSADH 153
- 6.4 Engineering of PAR for Increasing Activity in 2-Propanol/Water Medium 157
- 6.4.1 Construction of Sar268 Mutant 157
- 6.4.2 Construction of HAR1 Mutant 160
- 6.4.3 Characterization of Sar268 and HAR1 161
- 6.5 Application of Whole-Cell Biocatalysts Possessing Mutant PARs and LSADH 165
- 6.5.1 *E. coli* Whole-Cell Biocatalysts Possessing Mutant PARs and LSADH 165
- 6.5.2 Application of Immobilized *E. coli* Whole-Cell Catalysts to Continuous Production of Chiral Alcohol 168
- 6.5.3 Application of Immobilized *E. coli* Whole-Cell Catalysts (LSADH) for Regenerating NADH with IPA 171

6.6	Engineering of β -Keto Ester Reductase (KER) for Raising Thermal Stability and Stereoselectivity	172
6.6.1	Enzymatic Properties of KER	172
6.6.2	Engineering of KER and Characterization of Mutant Enzymes	175
6.7	New Approach for Engineering or Obtaining Useful ADHs/Reductases	177
6.7.1	Engineering the Coenzyme Dependency of Ketol-Acid Reductoisomerase (KARI)	177
6.7.2	Engineering Substrate- and Stereospecificity of Reductases by Structure-Guided Method	178
6.7.3	Engineering Database: Systematic Information of Sequence-Structure-Function	179
6.7.4	Metagenomics	180
	References	181
7	Synthetic Applications of Aminotransferases for the Preparation of Biologically Active Molecules	187
	<i>Sachin Pannuri, Sanjay Kamat, and Abraham R. Martín-García</i>	
7.1	Introduction	187
7.1.1	Aminotransferases	187
7.1.2	Transamination Reaction	188
7.1.3	Stereoselectivity of Aminotransferases	189
7.2	Applications	192
7.2.1	Biotransformation Process	192
7.2.2	Biologically Active Molecules	195
7.2.3	Process Economy	196
7.3	Challenges	196
7.3.1	Substrate Specificity	197
7.3.2	Improving Reaction Yield	197
7.3.3	Process Scale-Up	200
7.4	Future Research Needs	203
7.5	Conclusions	203
	References	204
8	Strategies for Cofactor Regeneration in Biocatalyzed Reductions	209
	<i>Selin Kara, Joerg H. Schrittwieser, and Frank Hollmann</i>	
8.1	Introduction: NAD(P)H as the Universal Reductant in Reduction Biocatalysis	209
8.2	The Most Relevant Cofactor Regeneration Approaches – and How to Choose the Most Suitable One	210
8.2.1	Electrochemical Regeneration of NAD(P)H	212
8.2.2	H ₂ as Reducing Agent	213
8.2.3	Formates as Reducing Agents	215
8.2.4	Phosphites as Stoichiometric Reductants	218
8.2.5	Alcohols as Stoichiometric Reductants	218

8.2.6	Glucose as Stoichiometric Reductant	223
8.3	Coupling the Reduction Reaction to a Regeneration Reaction Producing a Valuable Compound	225
8.4	Avoiding NAD(P)H: Does It Also Mean Avoiding the Challenge?	228
8.5	Conclusions	230
	References	231
9	Solvent Effects in Bioreductions	239
	<i>Yan Ni, Hui-Lei Yu, and Jian-He Xu</i>	
9.1	Introduction	239
9.2	Solvent Systems for Biocatalytic Reductions	240
9.2.1	Bioreduction in Aqueous Systems	240
9.2.2	Bioreduction in Monophasic Aqueous–Organic Systems	241
9.2.3	Bioreduction in Biphasic Aqueous–Organic Systems	243
9.2.4	Bioreduction in Micro- or Nonaqueous Systems	245
9.2.5	Bioreduction in Nonconventional Media	247
9.2.5.1	Ionic Liquids	247
9.2.5.2	Supercritical Fluids	250
9.2.5.3	Combining ILs and SFs	251
9.2.5.4	Gas-Phase Media	252
9.2.5.5	Reverse Micelles	254
9.3	Solvent Control of Enzyme Selectivity	255
9.4	Concluding Remarks	257
	References	258
10	Application of <i>In situ</i> Product Removal (ISPR) Technologies for Implementation and Scale-Up of Biocatalytic Reductions	263
	<i>John M. Woodley</i>	
10.1	Introduction	263
10.2	Process Requirements for Scale-Up	263
10.3	Bioreduction Process Engineering	265
10.4	<i>In situ</i> Product Removal	267
10.5	Biocatalyst Format	269
10.5.1	Whole-Cell Processes	271
10.5.2	Isolated Enzyme Processes	272
10.6	Selected Examples	273
10.6.1	ISPR with Resins	273
10.6.2	ISPR with Solvent Extraction	274
10.6.3	ISPR with Crystallization	274
10.6.4	Removal of Acetone	275
10.7	Future Outlook	276
10.7.1	Protein Engineering	276
10.7.2	Choice of Methods	277
10.7.3	Process Integration	278

10.8	Conclusions	280
	References	280
11	Bioreductions in Multienzymatic One-Pot and Cascade Processes	285
	<i>Daniela Monti and Erica E. Ferrandi</i>	
11.1	Introduction	285
11.2	Coupled Oxidation and Reduction Reactions	287
11.3	Consecutive and Cascade One-Pot Reductions	292
11.4	Cascade Processes, Including Biocatalyzed Reductive Amination Steps	296
11.5	Other Examples of Multienzymatic Cascade Processes, Including Bioreductive Reactions	302
	References	304
12	Dynamic Kinetic Resolutions Based on Reduction Processes	307
	<i>Dimitris Kalaitzakis and Ioulia Smonou</i>	
12.1	Introduction	307
12.2	Cyclic Compounds	309
12.3	Acyclic α -Substituted- β -Keto Esters and 2-Substituted-1,3-Diketones	313
12.4	Acyclic Ketones and Aldehydes	322
12.5	Conclusions	323
	References	324
13	Relevant Practical Applications of Bioreduction Processes in the Synthesis of Active Pharmaceutical Ingredients	329
	<i>Gábor Tasnádi and Mélanie Hall</i>	
13.1	Introduction	329
13.2	Ketoreductases	337
13.2.1	Ethyl 4-chloro-3-hydroxybutanoate	337
13.2.2	Atorvastatin	338
13.2.3	Montelukast	339
13.2.4	Ramatroban	340
13.2.5	Ezetimibe	341
13.2.6	Profens	342
13.2.7	Atazanavir	343
13.2.8	Chemokine Receptor Inhibitor	343
13.2.9	Duloxetine	344
13.2.10	6-Hydroxybuspirone	345
13.2.11	LY 300164	346
13.2.12	Paclitaxel	346
13.3	Ene Reductases	347
13.3.1	Levodopa	347
13.3.2	(+)-Dihydrocarvone	348
13.3.3	Butyrolactone – Jasplakinolide and Amphidinolides	348

13.3.4	(<i>R</i>)-Flurbiprofen	349
13.3.5	Ethyl (<i>S</i>)-2-ethoxy-3-(4-methoxyphenyl)propanoate – Tesaglitazar	350
13.3.6	Methyl (<i>Z</i>)-2-bromocrotonate – Antidiabetic Drug Candidates	350
13.3.7	Roche Ester	351
13.3.8	Human Neurokinin-1 Receptor Antagonists	352
13.3.9	Asymmetric Synthesis of Amino Acid Derivatives	353
13.4	Others	355
13.4.1	Amino Acid Dehydrogenase-Catalyzed Processes	355
13.4.1.1	Saxagliptin	355
13.4.1.2	Omapatrilat	356
13.4.1.3	Inogatran	357
13.4.1.4	Corticotropin-releasing Factor-1 (CRF-1) Receptor Antagonist	357
13.4.1.5	AG7088	358
13.4.2	Pyrrolo[2,1- <i>c</i>][1,4]benzodiazepines (Antitumor Agents)	358
13.4.3	Dihydrofolate Reductase	359
13.4.4	β -Carbolines	359
13.5	Bioreduction-Supported Processes	361
13.6	Outlook	363
	References	365
	Index	375